1 Dilatation of the cerebral vasculature is recognised to be involved in the pathophysiology of migraine. Furthermore, elevated levels of prostaglandin E 2 (PGE 2 ) occur in the blood, plasma and saliva of migraineurs during an attack, suggestive of a contributory role. In the present study, we have characterised the prostanoid receptors involved in the relaxation and contraction of human middle cerebral arteries in vitro. 2 In the presence of indomethacin (3 mM) and the TP receptor antagonist GR32191 (1 mM), PGE 2 was found to relax phenylephrine precontracted cerebral arterial rings in a concentration-dependent manner (mean pEC 50 8.070.1, n ¼ 5). 3 Establishment of a rank order of potency using the EP 4 4EP 2 agonist 11-deoxy PGE 1 , and the EP 2 4EP 4 agonist PGE 1 -OH (mean pEC 50 of 7.670.1 (n ¼ 6) and 6.470.1 (n ¼ 4), respectively), suggested the presence of functional EP 4 receptors. Furthermore, the selective EP 2 receptor agonist butaprost at concentrations o1 mM failed to relax the tissues. 4 Blockade of EP 4 receptors with the EP 4 receptor antagonists AH23848 and EP 4 A caused significant rightward displacements in PGE 2 concentration-response curves, exhibiting pA 2 and pK B values of 5.770.1, n ¼ 3, and 8.4, n ¼ 3, respectively. 5 The IP receptor agonists iloprost and cicaprost relaxed phenylephrine precontracted cerebral arterial rings (mean pEC 50 values 8.370.1 (n ¼ 4) and 8.170.1 (n ¼ 9), respectively). In contrast, the DP and FP receptor agonists PGD 2 and PGF 2a failed to cause appreciable relaxation or contraction at concentrations of up to 30 mM. In the absence of phenylephrine contraction and GR32191, the TP receptor agonist U46619 caused concentration-dependent contraction of cerebral artery (mean pEC 50 7.470.3, n ¼ 3). 6 These data demonstrate the presence of prostanoid EP 4 receptors mediating PGE 2 vasodilatation of human middle cerebral artery. IP receptors mediating relaxation and TP receptors mediating contraction were also functionally demonstrated.

Dual Bcl-2/Bcl-xL inhibitors are expected to deliver therapeutic benefit in many haematological and solid malignancies, however, their use is limited by tolerability issues. AZD4320, a potent dual Bcl-2/Bcl-xL inhibitor, has shown good efficacy however had dose limiting cardiovascular toxicity in preclinical species, coupled with challenging physicochemical properties, which prevented its clinical development. Here, we describe the design and development of AZD0466, a drug-dendrimer conjugate, where AZD4320 is chemically conjugated to a PEGylated poly-lysine dendrimer. Mathematical modelling was employed to determine the optimal release rate of the drug from the dendrimer for maximal therapeutic index in terms of preclinical anti-tumour efficacy and cardiovascular tolerability. The optimised candidate is shown to be efficacious and better tolerated in preclinical models compared with AZD4320 alone. The AZD4320-dendrimer conjugate (AZD0466) identified, through mathematical modelling, has resulted in an improved therapeutic index and thus enabled progression of this promising dual Bcl-2/Bcl-xL inhibitor into clinical development.

No abstract

No abstract

No abstract